TScan Therapeutics (TCRX) News Today

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) saw a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 1,020,000 shares, an increase of 67.7% from the June 30th total of 608,200 shares. Based on an average trading volume of 343,800 shares, the short-interest ratio is presently 3.0 days. Approximately 2.5% of the shares of the stock are sold short.

Tocqueville Asset Management L.P. acquired a new stake in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 212,200 shares of the company's stock,

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) saw a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 608,200 shares, an increase of 18.7% from the June 15th total of 512,400 shares. Based on an average daily trading volume, of 353,300 shares, the days-to-cover ratio is presently 1.7 days. Approximately 1.5% of the shares of the company are sold short.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) was the target of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 482,800 shares, a growth of 26.5% from the May 15th total of 381,800 shares. Currently, 1.2% of the company's shares are short sold. Based on an average daily volume of 209,200 shares, the days-to-cover ratio is presently 2.3 days.

TScan Therapeutics (NASDAQ:TCRX) Hits New 1-Year High at $9.55

BTIG Research began coverage on TScan Therapeutics in a research note on Thursday. They issued a "buy" rating and a $12.00 price target for the company.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at Lifesci Capital cut their FY2024 EPS estimates for TScan Therapeutics in a report issued on Monday, May 13th. Lifesci Capital analyst S. Slutsky now anticipates that the company will earn ($1.02) per share for the year,

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities researchers at Lifesci Capital issued their Q2 2024 earnings estimates for TScan Therapeutics in a research report issued on Monday, May 13th. Lifesci Capital analyst S. Slutsky expects that the company will post earnings per share o

HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note on Tuesday.

Wedbush reaffirmed an "outperform" rating and issued a $10.00 target price on shares of TScan Therapeutics in a report on Monday.

Needham & Company LLC reiterated a "buy" rating and set a $11.00 price target on shares of TScan Therapeutics in a research note on Monday.

abrdn plc bought a new stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 200,000 shares of the company's stock, valued at approximately $1,166,000. abrdn plc owned about 0.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 419,700 shares, an increase of 91.3% from the March 31st total of 219,400 shares. Based on an average daily volume of 193,600 shares, the short-interest ratio is currently 2.2 days. Currently, 1.1% of the shares of the stock are sold short.

Wedbush restated an "outperform" rating and issued a $10.00 target price on shares of TScan Therapeutics in a research note on Tuesday.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Analysts at Wedbush lowered their Q1 2024 earnings estimates for TScan Therapeutics in a research report issued to clients and investors on Wednesday, April 17th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.27)

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities research analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for shares of TScan Therapeutics in a research note issued to investors on Wednesday, April 17th. Wedbush analyst D. Nierengarten anticipates that t

Wedbush reissued an "outperform" rating and set a $10.00 target price on shares of TScan Therapeutics in a research report on Wednesday.